Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K

Rhea-AI Summary

Oragenics (NYSE American: OGEN), a biotechnology company focused on innovative treatments for concussion and brain-related health conditions, has filed its Annual Report on Form 10-K for the year ended December 31, 2024. The filing, submitted to the SEC on March 14, 2025, received an unqualified audit opinion from its independent registered public accounting firm.

However, the audit included an explanatory paragraph regarding the company's ability to continue as a going concern. The company states its commitment to advancing its pipeline, exploring strategic opportunities, and securing resources for long-term growth. Further details are available in Footnote 1 of the consolidated financial statements.

Positive

• Received unqualified audit opinion on consolidated financial statements

Negative

• Received going concern warning in audit report, indicating substantial doubt about company's ability to continue operations
• Company likely facing significant financial challenges requiring additional funding

SARASOTA, Fla., March 18, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions, today announced the filing of its Annual Report on Form 10-K for the year ended December 31, 2024, with the U.S. Securities and Exchange Commission on March 14, 2025.

The Company’s audited consolidated financial statements received an unqualified audit opinion from its independent registered public accounting firm. As part of the audit, an explanatory paragraph was included regarding the Company’s ability to continue as a going concern. Oragenics remains committed to advancing its innovative pipeline, exploring strategic opportunities, and securing the necessary resources to support its long-term growth. Additional details can be found in Footnote 1 of the consolidated financial statements included in the filing.

About Oragenics:

Oragenics is a development-stage biotechnology company focused on nasal delivery of pharmaceutical medications in neurology and fighting infectious diseases, including drug candidates for treating mild traumatic brain injury (mTBI), also known as concussion, and for treating Niemann Pick Disease Type C (NPC), as well as proprietary powder formulation and an intranasal delivery device. For more information, please visit www.oragenics.com.

Forward-Looking Statements

This communication contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to, those described in our Form 10-K and other filings with the U.S. Securities and Exchange Commission. All information set forth in this press release is as of the date hereof. You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. We do not assume any obligation to publicly provide revisions or updates to any forward-looking statements, whether as a result of new information, future developments or otherwise, should circumstances change, except as otherwise required by law.

Investor Contact

Rich Cockrell
Investor Relations
404.736.3838
OGEN@CG.CAPITAL

FAQ

What did the 2024 audit report reveal about Oragenics (OGEN) financial status?

While receiving an unqualified audit opinion, the report included a going concern warning, indicating significant uncertainty about the company's ability to continue operations.

When did Oragenics (OGEN) file its 2024 Annual Report?

Oragenics filed its 2024 Annual Report on Form 10-K with the SEC on March 14, 2025.

What is the current focus of Oragenics (OGEN) business?

Oragenics is a biotechnology company developing innovative treatments for concussion and brain-related health conditions.

What strategic steps is OGEN taking to address its financial concerns?

The company is committed to advancing its pipeline, exploring strategic opportunities, and securing necessary resources for long-term growth.